Disc Medicine to present DISC-0974 data at ASN Kidney Week

WATERTOWN, Mass. - Disc Medicine, Inc. (NASDAQ:IRON), whose stock has surged over 76% in the past six months and is currently trading near its 52-week high of $78.17, announced Friday it will present updated clinical data from its Phase 1b study of DISC-0974 at the 2025 American Society of Nephrology Kidney Week, scheduled for November 6-9 in Houston. According to InvestingPro, the company maintains strong financial health with a current ratio of 32.11, indicating robust liquidity.

The biopharmaceutical company, currently valued at $2.59 billion, will share results from all single and multiple-dose cohorts of its study examining DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia. The presentation will include safety and tolerability data, pharmacokinetics, and pharmacodynamic markers including changes to hepcidin, iron, and hematologic parameters. InvestingPro data reveals the company holds more cash than debt, with a minimal debt-to-equity ratio of 0.05.

Dr. Pablo Pergola will present the poster titled "A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Nondialysis-Dependent CKD and Anemia" on November 8.

"We look forward to returning to Kidney Week this year, where we will provide an update from our Phase 1b study of DISC-0974 in NDD-CKD patients with anemia," said John Quisel, President and Chief Executive Officer of Disc Medicine, in a press release statement.

The randomized, placebo-controlled study was designed to assess the effects of both single ascending and multiple doses of DISC-0974, which is an anti-hemojuvelin antibody.

Disc Medicine noted that while an abstract is currently available on the ASN Kidney Week conference website, it contains previously presented data, with new data and analyses reserved for the conference presentation.

The company focuses on developing treatments for serious hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. While analysts maintain a strong buy consensus with a high price target of $132, InvestingPro subscribers can access 13 additional investment tips and a comprehensive Pro Research Report for deeper insights into the company’s prospects. The stock’s recent performance and financial metrics suggest significant investor interest in its therapeutic pipeline.

In other recent news, Disc Medicine announced it has received a Commissioner’s National Priority Voucher (CNPV) from the U.S. Food and Drug Administration for its drug candidate bitopertin, aimed at treating erythropoietic protoporphyria (EPP). This voucher is part of a program designed to expedite drug review, potentially reducing the review period for new drug applications to one to two months. Following this development, several analyst firms have adjusted their outlook on Disc Medicine. Cantor Fitzgerald raised its price target for the company to $153 while maintaining an Overweight rating. H.C. Wainwright reiterated its Buy rating with a $118 price target, noting the significance of the FDA’s selection of bitopertin for the voucher. Raymond James also increased its price target to $108, maintaining a Strong Buy rating. Additionally, Leerink Partners raised its price target to $100, citing the FDA’s positive view of bitopertin’s New Drug Application. These recent developments reflect a positive reception from analysts following the FDA’s decision.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.